Search / Trial NCT00002210

A Study of Delavirdine Mesylate in Combination With Other Anti-HIV Drugs in HIV-Infected Children and Babies

Launched by PHARMACIA AND UPJOHN · Aug 30, 2001

Trial Information

Current as of December 06, 2024

Completed

Keywords

Hiv 1 Drug Therapy, Combination Delavirdine Reverse Transcriptase Inhibitors

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • Patients must have:
  • HIV infection.
  • Plasma HIV-1 levels greater than 10,000 copies/ml.

About Pharmacia And Upjohn

Pharmacia and Upjohn, a global biopharmaceutical company, specializes in the research, development, and commercialization of innovative therapies that address unmet medical needs across multiple therapeutic areas. With a strong commitment to advancing healthcare, the company leverages cutting-edge science and technology to improve patient outcomes. Pharmacia and Upjohn is dedicated to conducting rigorous clinical trials that adhere to the highest ethical standards, ensuring the safety and efficacy of its products while fostering collaboration with healthcare professionals and regulatory authorities worldwide. Through its comprehensive portfolio, the company aims to enhance the quality of life for patients and contribute to the advancement of medical science.

Locations

Peapack, New Jersey, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials